|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM185335349 |
| 003 |
DE-627 |
| 005 |
20250210012021.0 |
| 007 |
tu |
| 008 |
231223s2008 xx ||||| 00| ||chi c |
| 028 |
5 |
2 |
|a pubmed25n0618.xml
|
| 035 |
|
|
|a (DE-627)NLM185335349
|
| 035 |
|
|
|a (NLM)19099786
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a chi
|
| 100 |
1 |
|
|a Yu, Hui
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Randomized controlled multi-center trial for treatment of varicella in pediatric patients with hydrochloride valacyclovir
|
| 264 |
|
1 |
|c 2008
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 02.12.2010
|
| 500 |
|
|
|a Date Revised 01.12.2018
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a OBJECTIVE: To evaluate the efficacy and safety of hydrochloride valacyclovir in treatment of varicella in pediatric patients between April 2006 and March 2007
|
| 520 |
|
|
|a METHODS: A randomized controlled multi-center clinical trial was conducted in 5 pediatric centers, i.e., Children's Hospital of Fudan University, Children's Hospital of Zhejiang University, Children's Hospital of Nanjing Medical University, Pediatric Department of Tongji Hospital of Tongji Medical College, Huazhong University of Science & Technology and Children's Hospital, Chongqing University of Medical Sciences. Patients who were clinically diagnosed as varicella without any complications and were beyond 3 years of age were enrolled into the study from the out-patient clinics. The subjects were divided into two groups randomly, one was treated with hydrochloride valacyclovir, the other with ribavirin. There were 128 cases in the group treated with hydrochloride valacyclovir and 132 cases in control group treated with ribavirin. The treatment duration of two groups was five days. The clinical efficacy and safety were evaluated after the first day and the fourth day of the treatment and within three days after the end of the treatment. The clinical efficacy was assessed by efficacy index
|
| 520 |
|
|
|a RESULTS: (1) The efficacy index on the fourth day of the therapy (0.80 +/- 0.24) in the valacyclovir group was significantly higher than that of ribavirin control group (0.59 +/- 0.37) (t = 5.42, P < 0.01). The efficacy index at the end of the treatment (0.86 +/- 0.14) in the hydrochloride valacyclovir group was also significantly higher than that (0.70 +/- 0.30) of the ribavirin control group (t = 5.43, P < 0.01). (2) In the valacyclovir and ribavirin groups, the effective rates on the fourth day of the therapy were 94.53% and 72.7% respectively (chi2) = 22.38, P < 0.01). The effective rates at the end of the therapy were 99.2% and 88.6%, respectively (chi(2) = 12.60, P < 0.01). The rates of cure of the two groups were 33.6% and 25.0% (chi2) = 2.32, P > 0.05). (3) No severe adverse drug reactions were observed in any of the two groups
|
| 520 |
|
|
|a CONCLUSIONS: The hydrochloride valacyclovir was safe, reliable and convenient in treatment of uncomplicated varicella in children
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Multicenter Study
|
| 650 |
|
4 |
|a Randomized Controlled Trial
|
| 650 |
|
7 |
|a Antiviral Agents
|2 NLM
|
| 650 |
|
7 |
|a Valine
|2 NLM
|
| 650 |
|
7 |
|a HG18B9YRS7
|2 NLM
|
| 650 |
|
7 |
|a Valacyclovir
|2 NLM
|
| 650 |
|
7 |
|a MZ1IW7Q79D
|2 NLM
|
| 650 |
|
7 |
|a Acyclovir
|2 NLM
|
| 650 |
|
7 |
|a X4HES1O11F
|2 NLM
|
| 700 |
1 |
|
|a Zhu, Qi-rong
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Zhong-lin
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Li, Yue-fang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Xiao-hong
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Zhonghua er ke za zhi = Chinese journal of pediatrics
|d 1960
|g 46(2008), 6 vom: 22. Juni, Seite 454-6; discussion 456-7
|w (DE-627)NLM136249191
|x 0578-1310
|7 nnns
|
| 773 |
1 |
8 |
|g volume:46
|g year:2008
|g number:6
|g day:22
|g month:06
|g pages:454-6; discussion 456-7
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_20
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_31
|
| 912 |
|
|
|a GBV_ILN_39
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_50
|
| 912 |
|
|
|a GBV_ILN_61
|
| 912 |
|
|
|a GBV_ILN_65
|
| 912 |
|
|
|a GBV_ILN_69
|
| 912 |
|
|
|a GBV_ILN_70
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_120
|
| 912 |
|
|
|a GBV_ILN_130
|
| 912 |
|
|
|a GBV_ILN_227
|
| 912 |
|
|
|a GBV_ILN_244
|
| 912 |
|
|
|a GBV_ILN_285
|
| 912 |
|
|
|a GBV_ILN_294
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_665
|
| 912 |
|
|
|a GBV_ILN_813
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 46
|j 2008
|e 6
|b 22
|c 06
|h 454-6; discussion 456-7
|